Evidence map›Paper›PMID 30026327›Full record

ArticleCancer research2018

Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.

Fei Xing, Yin Liu, Shih-Ying Wu, Kerui Wu, Sambad Sharma, Yin-Yuan Mo, Jiamei Feng, Stephanie Sanders, Guangxu Jin, Ravi Singh and 10 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 208 papers.

0numbers the graph read from it
0cells of the map it votes in
208citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

208 citing papers in PubMed, 334 citations in OpenAlex.

  1. Article
  2. FASEB bioAdvances · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. NCancer communications (London, England) · 2025
    Article

148 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Fei Xing *Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina. kwatabe@wakehealth.edu fxing@wakehealth.edu.
Yin Liu *Department of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Shih-Ying WuDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Kerui WuDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Sambad SharmaDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Yin-Yuan MoDepartment of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi.
Jiamei FengMammary Department, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Stephanie SandersDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Guangxu JinDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Ravi SinghDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Pierre-Alexandre VidiDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.ORCID 0000-0002-9117-8896
Abhishek TyagiDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Michael D ChanDepartment of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Jimmy RuizDepartment of Hematology & Oncology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Waldemar DebinskiDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Boris C PascheDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Hui-Wen LoDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Linda J Metheny-BarlowDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina.
Ralph B D'AgostinoBiostatistical Sciences Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston Salem, NC.
Kounosuke WatabeDepartment of Cancer Biology, Wake Forest School of Medicine, Winston Salem, North Carolina. kwatabe@wakehealth.edu fxing@wakehealth.edu.
Wake Forest University · USShanghai University of Traditional Chinese Medicine · CNUniversity of Mississippi Medical Center · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Roles of hyaluronic acid in cancer stem cell nicheR01CA173499 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WATABE, KOUNOSUKE · 2014 to 2018
$2.3M
Roles of long-non-coding RNA, XIST, in brain metastasis of breast cancerR01CA205067 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WATABE, KOUNOSUKE · 2017 to 2021
$2.2M
Role of inflammation and microRNA network in brain metastasis of breast cancerR01CA185650 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WATABE, KOUNOSUKE · 2016 to 2020
$1.9M
Roles of neutrophils in c-Met mediated breast cancer brain metastasesR37CA230451 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI XING, FEI · 2018 to 2022
$1.8M
Development of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7M
Roles of miR29c-ID2 axis in tumor initiating cells of breast ductal carcinoma in situF31CA200286 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI LIU, YIN · 2016 to 2017
$88k
NCI NIH HHS F31 CA200286NCI NIH HHS P30 CA012197NCI NIH HHS R01 CA173499NCI NIH HHS R01 CA185650NCI NIH HHS R01 CA205067NCI NIH HHS R01 CA207222NCI NIH HHS R37 CA230451
6 · The paper itself

Abstract

Up to 30% of patients with metastatic breast cancer eventually develop brain metastasis, yet the pathologic mechanism behind this development remains poorly understood. Here, we profiled long noncoding RNAs in brain metastatic tumors from patients with breast cancer and found that the X-inactive-specific transcript (XIST) was significantly downregulated in these tissues. XIST expression levels inversely correlated with brain metastasis, but not with bone metastasis in patients. Silencing of XIST preferentially promoted brain metastatic growth of XIST

Indexed as

AnimalsBone NeoplasmsBrainBreast NeoplasmsCell Line, TumorCell ProliferationDown-RegulationEpithelial-Mesenchymal TransitionExosomesFemaleGene Expression Regulation, NeoplasticHumansMCF-7 CellsMiceMice, NudeMicrofilament ProteinsMicrofilament ProteinsMicroRNAsmoesinProto-Oncogene Proteins c-metRNA, Long NoncodingXIST non-coding RNA

Identifiers

PMID30026327
PMCPMC6072593
OpenAlexW2883027795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.